Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Assembly Biosciences Announced Interim Data From Several Cohorts From The Ongoing Phase 1a Trial Of ABI-6250 For Hepatitis Delta Virus

Author: Benzinga Newsdesk | August 06, 2025 05:05pm

Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement.
Further pharmacological assessment to be conducted in parallel with Phase 2 preparation

Posted In: ASMB